domperidone has been researched along with Adenoma in 26 studies
Domperidone: A specific blocker of dopamine receptors. It speeds gastrointestinal peristalsis, causes prolactin release, and is used as antiemetic and tool in the study of dopaminergic mechanisms.
domperidone : 1-[3-(Piperidin-1-yl)propyl]-1,3-dihydro-2H-benzimidazol-2-one in which the 4-position of the piperidine ring is substituted by a 5-chloro-1,3-dihydro-2H-benzimidazol-2-on-1-yl group. A dopamine antagonist, it is used as an antiemetic for the short-term treatment of nausea and vomiting, and to control gastrointestinal effects of dopaminergic drugs given in the management of parkinsonism. The free base is used in oral suspensions, while the maleate salt is used in tablet preparations.
Adenoma: A benign epithelial tumor with a glandular organization.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this study was to evaluate the usefulness of the domperidone test for the difficult diagnosis between functional and tumoral hyperprolactinemia." | 9.10 | Tumoral versus non-tumoral hyperprolactinemia in children and adolescents: possible usefulness of the domperidone test. ( Azaretzky, M; Boquete, HR; Fideleff, G; Fideleff, HL; Giaccio, AV; Honfi, M; Pujol, AB; Suárez, MG, 2003) |
| "To retrospectively analyze the individual risk factors for radioactive iodine (RAI)-associated nausea and vomiting, and to examine the anti-emetic effect of ramosetron (5-hydroxytryptamine-3 receptor antagonist) in RAI therapy." | 7.80 | Moderate to severe nausea in radioactive iodine (RAI) therapy is associated with the RAI dose per body weight and was not prevented by ramosetron. ( Ando, T; Ikeoka, T; Imaizumi, M; Kawakami, A; Ueki, I; Usa, T, 2014) |
| "Administration of a dopamine (DA) antagonist, domperidone, increased circulating levels of LH in hyperprolactinaemic-amenorrhoeic women with pituitary microadenomas but not in normal women in the early follicular phase of the menstrual cycle." | 7.67 | Luteinizing hormone response to domperidone in hyperprolactinaemic women with pituitary microadenomas. ( Kato, K; Seki, K, 1988) |
| "When domperidone was injected at the termination of DA infusion, the postinhibitory increases were significantly enhanced in either PRL-oma or normal subjects." | 5.27 | Modulation of postinhibitory increase in plasma prolactin by domperidone in patients with prolactin secreting adenoma. ( Goh, M; Hanew, K; Murakami, O; Sasaki, A; Sato, S; Shimizu, Y; Yoshinaga, K, 1985) |
| "The aim of this study was to evaluate the usefulness of the domperidone test for the difficult diagnosis between functional and tumoral hyperprolactinemia." | 5.10 | Tumoral versus non-tumoral hyperprolactinemia in children and adolescents: possible usefulness of the domperidone test. ( Azaretzky, M; Boquete, HR; Fideleff, G; Fideleff, HL; Giaccio, AV; Honfi, M; Pujol, AB; Suárez, MG, 2003) |
| "To retrospectively analyze the individual risk factors for radioactive iodine (RAI)-associated nausea and vomiting, and to examine the anti-emetic effect of ramosetron (5-hydroxytryptamine-3 receptor antagonist) in RAI therapy." | 3.80 | Moderate to severe nausea in radioactive iodine (RAI) therapy is associated with the RAI dose per body weight and was not prevented by ramosetron. ( Ando, T; Ikeoka, T; Imaizumi, M; Kawakami, A; Ueki, I; Usa, T, 2014) |
| " Because D2(High) receptors have not yet been detected in intact cells, we used [(3)H]domperidone to detect D2(High) sites in intact rat anterior pituitary adenoma culture cells." | 3.74 | Dopamine D2(High) receptors on intact cells. ( Seeman, P, 2008) |
| "Administration of a dopamine (DA) antagonist, domperidone, increased circulating levels of LH in hyperprolactinaemic-amenorrhoeic women with pituitary microadenomas but not in normal women in the early follicular phase of the menstrual cycle." | 3.67 | Luteinizing hormone response to domperidone in hyperprolactinaemic women with pituitary microadenomas. ( Kato, K; Seki, K, 1988) |
| "To verify the diagnostic capacity of some dynamic tests of the prolactin (Prl) secretion, the findings obtained by high-resolution computed tomography (CT) were compared with results obtained from tests using nomifensine (NOM) domperidone (DOM) and thyrotrophin-releasing hormone (TRH) in 72 patients with pathological hyperprolactinaemia." | 3.67 | Comparison between pituitary computed tomographic findings and tests of hypothalamo-pituitary function in 72 patients with hyperprolactinaemia. ( Bianchi, SD; Camanni, F; Ciccarelli, E; Gatti, G; Ghigo, E; Massara, F; Molinatti, GM; Müller, EE, 1986) |
| " Preoperatively in patients with prolactinomas (n = 33) the TSH response to domperidone decreased with increasing adenoma size." | 3.67 | The preoperative and postoperative investigation of TSH and prolactin release in the management of patients with hyperprolactinaemia due to prolactinomas and nonfunctional pituitary tumours: relationship to adenoma size at surgery. ( Hall, R; Howell, S; John, R; Peters, JR; Richards, SH; Salvador, J; Scanlon, MF; Thomas, JP; Williams, ED, 1986) |
| " Twenty-six women diagnosed by dynamic tests and radiologic examination as having PRL-secreting adenoma were treated surgically (15) or with bromocriptine (11) and their condition was evaluated one to three years later by TRH, nomifensine, and domperidone tests." | 3.67 | Prolactin secretion after surgery or bromocriptine treatment of prolactinoma. ( D'Antona, N; Danero, S; De Leo, V; Genazzani, AR; Petraglia, F; Sardelli, S, 1987) |
| "The response to domperidone (a dopamine blocking agent) of serum prolactin (PRL) levels was compared in 3 patients with amenorrhea-galactorrhea without evidence of a pituitary tumor, 23 patients with prolactinomas (10 cases with histologic confirmation), 7 patients with histologically verified large nonfunctioning pituitary adenomas with normal or moderately elevated basal PRL levels, and 6 patients with histologically verified craniopharyngiomas (3 with normal basal PRL levels and 3 with elevated PRL levels)." | 3.67 | Dysfunction of dopaminergic regulation of prolactin in patients with functioning and nonfunctioning pituitary adenomas and craniopharyngiomas. ( Cornejo, J; Garza-Flores, J; Martinez-Campos, A; Velasco, F, 1985) |
| "Fifteen normal menstruating women in the early follicular phase of their menstrual cycle, fifteen patients with prolactin secreting adenomas, two patients with a suprahypophysial lesion and an hyperprolactinemia, underwent a dopamine infusion (4 micrograms/kg/mn for four hours and an orally administration of domperidone (40 mg)." | 3.66 | [Kinetics of prolactinemia after withdrawal of dopamine perfusion and during the administration of domperidone. Normal and hyperprolactinemic subjects (prolactinomas and suprahypophyseal lesions)]. ( Bercovici, JP; Besson, G; Caroff, J; Khoury, S; Tater, D, 1983) |
| " The intensity of dopamine (DA) effects on the pituitary around the adenoma was evaluated by measuring thyroid stimulating hormone (TSH) responses to intravenous injection of domperidone (10 mg) a new DA receptor blocking drug that does not penetrate the blood-brain barrier." | 3.66 | Altered dopaminergic regulation of thyrotrophin release in patients with prolactinomas: comparison with other tests of hypothalamic-pituitary function. ( Cook, DB; Gomez-Pan, A; Hall, R; Lewis, M; McGregor, AM; Rodriguez-Arnao, MD; Scanlon, MF; Weightman, D, 1981) |
| "When domperidone was injected at the termination of DA infusion, the postinhibitory increases were significantly enhanced in either PRL-oma or normal subjects." | 1.27 | Modulation of postinhibitory increase in plasma prolactin by domperidone in patients with prolactin secreting adenoma. ( Goh, M; Hanew, K; Murakami, O; Sasaki, A; Sato, S; Shimizu, Y; Yoshinaga, K, 1985) |
| " The direct control of GH secretion at the pituitary level has been observed using human GH-secreting pituitary adenomas in organ culture, but no dose-response relationship between DA and GH inhibition was demonstrated." | 1.26 | Evidence of dopamine receptors in human growth hormone (GH)-secreting adenomas with concomitant study of dopamine inhibition of GH secretion in a perifusion system. ( Brandi, AM; Bression, D; Le Dafniet, M; Nousbaum, A; Peillon, F; Racadot, J, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 22 (84.62) | 18.7374 |
| 1990's | 1 (3.85) | 18.2507 |
| 2000's | 2 (7.69) | 29.6817 |
| 2010's | 1 (3.85) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ikeoka, T | 1 |
| Ando, T | 1 |
| Imaizumi, M | 1 |
| Ueki, I | 1 |
| Usa, T | 1 |
| Kawakami, A | 1 |
| Fideleff, HL | 1 |
| Azaretzky, M | 1 |
| Boquete, HR | 1 |
| Pujol, AB | 1 |
| Honfi, M | 1 |
| Suárez, MG | 1 |
| Fideleff, G | 1 |
| Giaccio, AV | 1 |
| Seeman, P | 1 |
| Camanni, F | 5 |
| Ghigo, E | 4 |
| Ciccarelli, E | 4 |
| Massara, F | 3 |
| Campagnoli, C | 1 |
| Molinatti, G | 1 |
| Müller, EE | 6 |
| Chanson, P | 1 |
| Orgiazzi, J | 1 |
| Derome, PJ | 1 |
| Bression, D | 3 |
| Jedynak, CP | 1 |
| Trouillas, J | 1 |
| Legentil, P | 1 |
| Racadot, J | 3 |
| Peillon, F | 3 |
| Rodriguez-Arnao, MD | 2 |
| Peters, JR | 2 |
| Foord, SM | 1 |
| Dieguez, C | 1 |
| Edwards, C | 1 |
| Gomez-Pan, A | 2 |
| Hall, R | 3 |
| Newcombe, RG | 1 |
| Scanlon, MF | 3 |
| Bercovici, JP | 1 |
| Khoury, S | 1 |
| Tater, D | 1 |
| Besson, G | 1 |
| Caroff, J | 1 |
| McGregor, AM | 1 |
| Weightman, D | 1 |
| Lewis, M | 1 |
| Cook, DB | 2 |
| De Gennes, JL | 1 |
| Turpin, G | 1 |
| Heshmati, HM | 1 |
| Carayon, A | 1 |
| Brandi, AM | 2 |
| Nousbaum, A | 2 |
| Le Dafniet, M | 1 |
| De Leo, V | 3 |
| Massafra, C | 1 |
| La Marca, S | 1 |
| De Leo, M | 1 |
| Venturi, C | 1 |
| Urbani, TM | 1 |
| Genazzani, AR | 3 |
| Molinatti, GM | 2 |
| Martres, MP | 1 |
| Cesselin, F | 1 |
| Miola, C | 1 |
| Gandini, G | 1 |
| Bevan, JS | 1 |
| Burke, CW | 1 |
| Esiri, MM | 1 |
| Adams, CB | 1 |
| Ballabio, M | 1 |
| Nissim, M | 2 |
| Faglia, G | 2 |
| Seki, K | 1 |
| Kato, K | 1 |
| Bianchi, SD | 1 |
| Gatti, G | 1 |
| Salvador, J | 1 |
| Richards, SH | 1 |
| John, R | 1 |
| Howell, S | 1 |
| Williams, ED | 1 |
| Thomas, JP | 1 |
| Petraglia, F | 1 |
| Sardelli, S | 1 |
| Danero, S | 1 |
| D'Antona, N | 1 |
| Moriondo, P | 1 |
| Travaglini, P | 1 |
| Conti, A | 1 |
| Prescott, RW | 1 |
| Johnston, DG | 1 |
| Taylor, PK | 1 |
| Haigh, J | 1 |
| Weightman, DR | 1 |
| Hall, K | 1 |
| Hanew, K | 1 |
| Sato, S | 1 |
| Sasaki, A | 1 |
| Goh, M | 1 |
| Shimizu, Y | 1 |
| Murakami, O | 1 |
| Yoshinaga, K | 1 |
| Novelli, A | 1 |
| Massobrio, M | 1 |
| Cocchi, D | 1 |
| Peñalva, A | 1 |
| Torpia, R | 1 |
| Rossi, GL | 1 |
| Israel, JM | 1 |
| Jaquet, P | 1 |
| Vincent, JD | 1 |
| Martinez-Campos, A | 1 |
| Cornejo, J | 1 |
| Garza-Flores, J | 1 |
| Velasco, F | 1 |
2 trials available for domperidone and Adenoma
| Article | Year |
|---|---|
Tumoral versus non-tumoral hyperprolactinemia in children and adolescents: possible usefulness of the domperidone test.
Topics: Adenoma; Adolescent; Child; Domperidone; Dopamine Antagonists; Female; Humans; Hyperprolactinemia; M | 2003 |
Exaggerated circadian variation in basal thyrotropin (TSH) and in the dopaminergic inhibition of TSH release in pathological hyperprolactinemia: evidence against a hypothalamic dopaminergic defect.
Topics: Adenoma; Adolescent; Adult; Circadian Rhythm; Domperidone; Dopamine; Female; Humans; Hypothalamus; M | 1983 |
24 other studies available for domperidone and Adenoma
| Article | Year |
|---|---|
Moderate to severe nausea in radioactive iodine (RAI) therapy is associated with the RAI dose per body weight and was not prevented by ramosetron.
Topics: Adenoma; Adult; Aged; Antiemetics; Benzimidazoles; Domperidone; Dose-Response Relationship, Radiatio | 2014 |
Dopamine D2(High) receptors on intact cells.
Topics: Adenoma; Animals; Binding, Competitive; Corpus Striatum; Domperidone; Dopamine Antagonists; Pituitar | 2008 |
Defective regulation of prolactin secretion after successful removal of prolactinomas.
Topics: Adenoma; Adult; Domperidone; Female; Humans; Male; Nomifensine; Pituitary Neoplasms; Pregnancy; Prol | 1983 |
Paradoxical response of thyrotropin to L-dopa and presence of dopaminergic receptors in a thyrotropin-secreting pituitary adenoma.
Topics: Adenoma; Adult; Domperidone; Female; Humans; In Vitro Techniques; Levodopa; Pituitary Neoplasms; Rec | 1984 |
[Kinetics of prolactinemia after withdrawal of dopamine perfusion and during the administration of domperidone. Normal and hyperprolactinemic subjects (prolactinomas and suprahypophyseal lesions)].
Topics: Adenoma; Adult; Domperidone; Dopamine; Female; Follicular Phase; Humans; Kinetics; Pituitary Disease | 1983 |
Altered dopaminergic regulation of thyrotrophin release in patients with prolactinomas: comparison with other tests of hypothalamic-pituitary function.
Topics: Adenoma; Adolescent; Adult; Benzimidazoles; Domperidone; Female; Growth Hormone; Humans; Hydrocortis | 1981 |
[Progress in the hormonal detection of pituitary prolactin adenoma].
Topics: Adenoma; Bromocriptine; Domperidone; Humans; Metoclopramide; Nomifensine; Pituitary Neoplasms; Prola | 1982 |
Evidence of dopamine receptors in human growth hormone (GH)-secreting adenomas with concomitant study of dopamine inhibition of GH secretion in a perifusion system.
Topics: Adenoma; Apomorphine; Domperidone; Dopamine; Dose-Response Relationship, Drug; Growth Hormone; Human | 1982 |
[Indirect dopamine agonists and direct dopamine antagonists in the diagnosis of hyperprolactinemia].
Topics: Adenoma; Adult; Domperidone; False Negative Reactions; False Positive Reactions; Female; Humans; Iso | 1982 |
Tests of prolactin secretion in the diagnosis of hyperprolactinemic states: nomifensine and domperidone.
Topics: Adenoma; Adult; Benzimidazoles; Domperidone; Female; Humans; Isoquinolines; Male; Menstruation; Midd | 1981 |
Dopaminergic receptors in human prolactin-secreting adenomas: a quantitative study.
Topics: Adenoma; Adolescent; Adult; Aged; Benzimidazoles; Binding, Competitive; Cell Membrane; Domperidone; | 1980 |
Long-term follow-up of 'cured' prolactinoma patients after successful adenomectomy.
Topics: Adenoma; Adrenalectomy; Adult; Domperidone; Dopamine Antagonists; Female; Follow-Up Studies; Humans; | 1990 |
Studies of two thyrotrophin-secreting pituitary adenomas: evidence for dopamine receptor deficiency.
Topics: Adenoma; Adult; Biological Assay; Bromocriptine; Chromatography, Gel; Domperidone; Female; Humans; I | 1989 |
Luteinizing hormone response to domperidone in hyperprolactinaemic women with pituitary microadenomas.
Topics: Adenoma; Adult; Domperidone; Female; Follicular Phase; Humans; Hyperprolactinemia; Luteinizing Hormo | 1988 |
Comparison between pituitary computed tomographic findings and tests of hypothalamo-pituitary function in 72 patients with hyperprolactinaemia.
Topics: Adenoma; Adolescent; Adult; Domperidone; Female; Humans; Hyperprolactinemia; Hypothalamo-Hypophyseal | 1986 |
The preoperative and postoperative investigation of TSH and prolactin release in the management of patients with hyperprolactinaemia due to prolactinomas and nonfunctional pituitary tumours: relationship to adenoma size at surgery.
Topics: Adenoma; Adult; Aged; Domperidone; Female; Humans; Male; Middle Aged; Pituitary Neoplasms; Postopera | 1986 |
Prolactin secretion after surgery or bromocriptine treatment of prolactinoma.
Topics: Adenoma; Adult; Bromocriptine; Domperidone; Female; Humans; Hypophysectomy; Nomifensine; Pituitary N | 1987 |
Bromocriptine treatment of microprolactinomas: evidence of stable prolactin decrease after drug withdrawal.
Topics: Adenoma; Adolescent; Adult; Bromocriptine; Domperidone; Dose-Response Relationship, Drug; Female; Hu | 1985 |
The inability of dynamic tests of prolactin and TSH secretion to differentiate between tumorous and non-tumorous hyperprolactinemia.
Topics: Adenoma; Adolescent; Adult; Blood Glucose; Diagnosis, Differential; Domperidone; Female; Humans; Ins | 1985 |
Modulation of postinhibitory increase in plasma prolactin by domperidone in patients with prolactin secreting adenoma.
Topics: Adenoma; Adolescent; Adult; Domperidone; Dopamine; Female; Humans; Hyperprolactinemia; Male; Pituita | 1985 |
Prolactin and thyrotropin response to blockade of dopamine synthesis by monoiodotyrosine in subjects with postpartum and pathological hyperprolactinemia.
Topics: Adenoma; Adult; Animals; Binding, Competitive; Domperidone; Dopamine; Female; Humans; In Vitro Techn | 1985 |
Persistence of a defective tuberoinfundibular dopaminergic function in rats after long-term removal of oestrogen treatment. An in vivo study.
Topics: Adenoma; Animals; D-Ala(2),MePhe(4),Met(0)-ol-enkephalin; Domperidone; Estradiol; Female; Hypothalam | 1985 |
The electrical properties of isolated human prolactin-secreting adenoma cells and their modification by dopamine.
Topics: Adenoma; Bromocriptine; Domperidone; Dopamine; Dose-Response Relationship, Drug; Electrophysiology; | 1985 |
Dysfunction of dopaminergic regulation of prolactin in patients with functioning and nonfunctioning pituitary adenomas and craniopharyngiomas.
Topics: Adenoma; Adolescent; Adult; Amenorrhea; Craniopharyngioma; Domperidone; Dopamine; Female; Galactorrh | 1985 |